Tanguy Seiwert, MD
Enriched profileDirector, Head and Neck Cancer Disease Group and Co-Director, Bloomberg~Kimmel Institute for Immunotherapy (Head and Neck Cancer Program), Johns Hopkins School of Medicine · Johns Hopkins University
Tanguy Seiwert is Director, Head and Neck Cancer Disease Group and Co-Director, Bloomberg~Kimmel Institute for Immunotherapy (Head and Neck Cancer Program), Johns Hopkins School of Medicine at Johns Hopkins University. OpenAlex indexes 402 publications with 23,345 citations (h-index 60); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
Tanguy Seiwert, M.D., is Director, Head and Neck Cancer Disease Group and Co-Director, Bloomberg~Kimmel Institute for Immunotherapy (Head and Neck Cancer Program), Johns Hopkins School of Medicine at Johns Hopkins University / Johns Hopkins School of Medicine, Baltimore, MD. The public record shows 402 publications with 23,345 citations (h-index 60), centered on Head and Neck Cancer Studies, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 21 companies.
- Most recent indexed publication: 2025 · Cancer research communications
- Top research focus: Head and Neck Cancer Studies
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 21 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 18 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 170.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy
Sponsor: University of Chicago
- Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck
Sponsor: University of Chicago
Industry payments
Updated 16 Oct 2026
21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20258 payments
- ABBVIE INC.Program year20251 payment
- AstraZeneca UK LimitedProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
40%Phenothiazine27.4%Prochlorperazine Maleate100%Part D≥24 patientsOpioid Agonist12.6%Oxycodone Hcl100%Part D<11 patientsHormonal (systemic)
34.8%l-Thyroxine34.8%Levothyroxine Sodium100%Part D≥14 patientsSensory organs
17%Corticosteroid17%Dexamethasone100%Part D≥18 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 16 Oct 2026
138 congress contributions (2005–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.
Cancer research communications
Article2025 - INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Clinical cancer research
Clinical Trial2025 - Lower survival for surgical treatment of human papillomavirus-related oropharynx cancer at community cancer centers.
Journal of the National Cancer Institute
Article2025 - Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade.
Journal for immunotherapy of cancer
Article2025
Most-cited works
by citation count (OpenAlex)- 01IFN-γ–related mRNA profile predicts clinical response to PD-1 blockadeArticle3,916 citations2017
- 02Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapyArticle2,370 citations2018
- 03
- 04
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/tanguy-lim-seiwert-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Doximity
doximity.com/pub/tanguy-seiwert-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
hopkinsmedicine.org/kimmel-cancer-center/bloomberg-kimmel-institute-for-cancer-immunotherapy/team
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hopkinsmedicine.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- M.D.
Johannes Gutenberg University Mainz Faculty of Medicine (corroborates NPI-registry M.D. credential)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.usnews.com ↗ - Board certified
Medical Oncology (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - Board certified
Internal Medicine (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- Chief Editor
Frontiers in Head and Neck Cancer
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗ - Editorial board member
Journal of Clinical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗ - Editorial board member
Oral Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗
Awards & honors
honors on the public record- IASLC Fellowship Award (2007) for research on Heat Shock Protein 27 as a novel therapeutic target in lung cancer
while at University of Chicago
2007provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →iaslc.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerresearchfdn.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →old-prod.asco.org ↗
Secondary affiliations
appointments beyond the home institution- Joint faculty appointment
Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine (in addition to primary Medical Oncology appointment)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →orcid.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- Recurring video interview contributor on head and neck cancer immunotherapy and clinical trials
OncLive (author archive)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Recurring video/article contributor
Targeted Oncology (author archive)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Evan Lipson, MD
Johns Hopkins University
Pradeep Ramulu, MD
Johns Hopkins University
Nicholas Maragakis, MD
Johns Hopkins University
Michael Pishvaian, MD
Johns Hopkins University
Everett Vokes, MD
University of Chicago
Maura Gillison, MD
The University of Texas MD Anderson Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Francis Worden, MD
University of Michigan Rogel Cancer Center